Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2017 / Cilt: 27 - Sayı: 2

Küçük Hücreli Dışı Akciğer Kanseri’nde ERCC1’in Prognostic Rolü ve 18F-FDG Tutulumu ile Korelasyonu

Prognostic Role of ERCC1 Protein Expression and its Correlation with 18F-FDG Uptake on PET in Patients with Resected Non-Small Cell Lung Cancer

Pages
110–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The association between high 18F-FDG uptake on PET and poor outcome was confirmed, but we failed to detect a powerful correlation between ERCC1 expression and SUVmax

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ERCC1 is a protein which is found to be associated with resistance to platinum-based chemotherapy.
📊
Key Findings & Data:The aim of this study is to examine both prognostic values of ERCC1 expression and 18F-FDG uptake on PET and their relationship in patients who underwent pulmonary resection for NSCLC.
💡
Conclusion & Impact:The association between high 18F-FDG uptake on PET and poor outcome was confirmed, but we failed to detect a powerful correlation between ERCC1 expression and SUVmax
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

ERCC1 is a protein which is found to be associated with resistance to platinum-based chemotherapy. FDG uptake is considered as a prognostic marker in patients with NSCLC and provides information beyond that of TNM staging. The aim of this study is to examine both prognostic values of ERCC1 expression and 18F-FDG uptake on PET and their relationship in patients who underwent pulmonary resection for NSCLC. Although high expression of ERCC1 was found to be associated with better survival, the difference was not considered as statistically significant (p= 0.067). There is a significant survival advantage in ERCC1 (+) patients who did not receive adjuvant therapy (p= 0.047). High maximal standard uptake value (SUVmax) was found to be associated with poor survival (hazard ratio [HR]: 1.10; 95% CI, 1.02-1.18; p= 0.009). Correlation between ERCC1 expression and mean SUVmax was statistically insignificant (p= 0.915). Among patients with SUVmax ≥2.5, ERCC1 positivity was 57.4% in patients who survived and 29.4% in patients who died which was statistically significant (p= 0.048). The association between high 18F-FDG uptake on PET and poor outcome was confirmed, but we failed to detect a powerful correlation between ERCC1 expression and SUVmax

Özet

ERCC1 protein pozitifliği ile platin bazlı kemoterapi arasında direnç olduğu bulunmuştur. FDG tutulumunun ise KHDAK'da prognostik bir belirteç olduğu, TNM sınıflamasının ötesinde prognostik bilgi verdiği kabul edilmektedir. Bu çalışmanın amacı, KHDAK nedeniyle akciğer rezeksiyonu uy-gulanmış olan hastalarda hem ERCC1 proteininin prognostik değerinin hem de ERCC1 ekspresyonunun PET'te 18F-FDG tutulumu ile olan korelasyonunu araştırılmasıdır. KHDAK tanısıyla PET sonrası akciğer rezeksiyonu uygulanmış olan 71 hasta retrospektif olarak incelendi. ERCC1 ekspresyonu olan hastaların sağkalımı istatistiksel olarak anlamlı olmasa da daha iyi bulundu (p= 0.067). Adjuvan tedavi almayan hastalarda ERCC1 pozitif hastalarda anlamlı sağkalım avantajı olduğu görüldü (p= 0.047). Yüksek SUVmax değerleri kötü prognozu gösterdi (hazard ratio [HR]: 1.10; 95% CI, 1.02-1.18; p= 0.009). ERCC1 ekspresyonu ile ortalama SUVmax değerleri arasında anamlı korelasyon saptanmadı (p= 0.915). SUVmax >=2.5 olan hastalarda, ölen hastalarda ERCC1 pozitifliği %57.4, yaşayan hastalarda %29.4 olarak saptandı (p= 0.048). Yüksek 18F-FDG tutulumu değerleri ile kötü prognoz ilişkisi bu çalışma ile tekrar gösterilmiş oldu. Ancak, ERCC1 ekspresyonu ile SUVmax değerleri arasında güçlü bir korelasyon saptanamadı

🔖

Cite This Article

ŞAHİNOĞLU, T., UYSAL, S., KUMBASAR, U., ONDER, S. C., DOĞAN, R., PAŞAOĞLU, İ., DEMİRCİN, M. (2017). Küçük Hücreli Dışı Akciğer Kanseri’nde ERCC1’in Prognostic Rolü ve 18F-FDG Tutulumu ile Korelasyonu. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 27 - Sayı: 2, 110–117. https://ajindex.com/articles/323141

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 64: 252-271, 2014
  2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemi-ology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008
  3. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 130: 1211-1219, 2006
  4. D’Addario G, Felip E, Group EGW. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 4: 68-70, 2004
  5. Saisho S, Yasuda K, Maeda A, et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg 16: 166-172, 2013
  6. Stewart DJ, Chiritescu G, Dahrouge S, et al. Chemotherapy dose response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33: 101- 137, 2007
  7. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127: 978-983, 2005
  8. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006
  9. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene ex-pression and platinum resistance. Int J Mol Med 14: 959-970, 2004